NASDAQ:ARGS - Argos Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.05 -0.01 (-16.67 %) (As of 12/14/2018 04:00 PM ET)Previous Close$0.0590Today's Range$0.05 - $0.068052-Week Range$0.07 - $4.00Volume4,732 shsAverage Volume345,759 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. Receive ARGS News and Ratings via Email Sign-up to receive the latest news and ratings for ARGS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARGS Previous Symbol CUSIPN/A Webwww.argostherapeutics.com Phone919-287-6300 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees39 Outstanding Shares10,590,000Market Cap$0.00 OptionableNot Optionable Argos Therapeutics (NASDAQ:ARGS) Frequently Asked Questions What is Argos Therapeutics' stock symbol? Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS." When did Argos Therapeutics' stock split? How did Argos Therapeutics' stock split work? Shares of Argos Therapeutics reverse split on the morning of Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of Argos Therapeutics stock prior to the reverse split would have 5 shares after the split. How were Argos Therapeutics' earnings last quarter? Argos Therapeutics Inc. (NASDAQ:ARGS) posted its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) earnings per share for the quarter, topping the Zacks' consensus estimate of ($4.50) by $0.30. The biopharmaceutical company earned $0.07 million during the quarter, compared to the consensus estimate of $0.10 million. View Argos Therapeutics' Earnings History. Has Argos Therapeutics been receiving favorable news coverage? Media stories about ARGS stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Argos Therapeutics earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the company's share price in the next few days. Who are some of Argos Therapeutics' key competitors? Some companies that are related to Argos Therapeutics include Advanced Accelerator Application (AAAP), Aerpio Pharmaceuticals (ARPO), AgeX Therapeutics (AGE), Anthera Pharmaceuticals (ANTH), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Egalet (EGLT), Eleven Biotherapeutics (EBIO) and Immune Pharmaceuticals (IMNP). Who are Argos Therapeutics' key executives? Argos Therapeutics' management team includes the folowing people: Mr. Jeffrey D. Abbey, Pres, CEO & Director (Age 56)Dr. Charles A. Nicolette Ph.D., Chief Scientific Officer and VP of R&D (Age 56)Dr. Richard D. Katz, VP & CFO (Age 54)Ms. Lori R. Harrelson CPA, VP of Fin. & Principal Accounting Officer (Age 49)Mr. John D. Menditto, VP of Corp. Communications and Investor Relations How do I buy shares of Argos Therapeutics? Shares of ARGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Argos Therapeutics' stock price today? One share of ARGS stock can currently be purchased for approximately $0.05. What is Argos Therapeutics' official website? The official website for Argos Therapeutics is http://www.argostherapeutics.com. How can I contact Argos Therapeutics? Argos Therapeutics' mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The biopharmaceutical company can be reached via phone at 919-287-6300. MarketBeat Community Rating for Argos Therapeutics (NASDAQ ARGS)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 270 (Vote Outperform)Underperform Votes: 169 (Vote Underperform)Total Votes: 439MarketBeat's community ratings are surveys of what our community members think about Argos Therapeutics and other stocks. Vote "Outperform" if you believe ARGS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2018 by MarketBeat.com StaffFeatured Article: Are all No-Load Funds Equal?